Hero Image

Pulmonary Arterial Hypertension: Signs, Risks, Treatment

Pulmonary Arterial Hypertension (PAH) is a serious, progressive condition in which high pressure builds up in the arteries that carry blood from your heart to your lungs.

Catching the signs early—and acting on them—can slow progression, preserve right-heart function, and open the door to more effective, less invasive treatments.

Early signs you shouldn’t ignore

PAH often starts subtly. Many people first notice shortness of breath on hills or stairs, unusual fatigue, chest pressure, palpitations, or lightheadedness during routine activities. These symptoms are easy to blame on anxiety, low fitness, or asthma, which is why PAH is frequently diagnosed late. Trusted resources such as the NHLBI and the Pulmonary Hypertension Association (PHA) stress that persistent, progressive breathlessness deserves evaluation.

Clues that it’s more than being “out of shape” include symptoms that steadily worsen, longer recovery after exertion, swelling in the ankles or belly, bluish lips or fingers, or near-fainting during activity—especially if you also notice a racing heartbeat. Keep a simple symptom journal to track what you can do comfortably (distance walked, stairs climbed) and note any dizziness, chest discomfort, or swelling.

Seek testing if symptoms persist beyond 6–8 weeks, escalate quickly, or appear alongside risk factors such as connective tissue disease (e.g., scleroderma), congenital heart disease, HIV, portal hypertension, prior methamphetamine or appetite-suppressant exposure, or a family history of PAH. If you’re concerned, start with your primary clinician and ask about referral to an experienced pulmonary hypertension center; the PHA’s Care Center directory can help you locate one.

  • Breathlessness on exertion (early) and at rest (later)
  • Fatigue and reduced exercise capacity
  • Chest pain/pressure, palpitations
  • Lightheadedness or fainting with activity
  • Leg/ankle swelling or abdominal bloating
  • Cold hands/feet, bluish lips or fingers

What causes PAH—and who’s at risk?

PAH (Group 1 pulmonary hypertension) can be idiopathic (no known cause), heritable (often involving BMPR2 variants), or associated with conditions such as systemic sclerosis and other connective tissue diseases, congenital heart shunts, HIV, portal hypertension, and certain drugs/toxins. Females are affected more often than males. Importantly, other types of pulmonary hypertension—due to left-heart disease, chronic lung disease, sleep apnea, or chronic blood clots—can mimic PAH. Sorting this out matters because treatments differ by group.

If you live with a known risk condition (for example, scleroderma), talk with your specialist about screening. Periodic echocardiograms and blood biomarkers (BNP or NT-proBNP) may detect changes earlier in high-risk populations, allowing timely intervention.

How PAH is diagnosed (and why speed matters)

A targeted workup rules out common lookalikes and confirms PAH. Your clinician may order an echocardiogram, ECG, lab tests (BNP/NT-proBNP), pulmonary function tests, and a ventilation–perfusion (V/Q) scan to check for chronic blood clots. For clot screening, a V/Q scan is often preferred over CT; here’s a plain-language overview from RadiologyInfo.org.

Definitive diagnosis requires a right heart catheterization to directly measure pressures and cardiac output. Some patients undergo vasoreactivity testing during this procedure to see whether high-dose calcium channel blockers might help; this should only be done in experienced centers. Learn more about right heart catheterization from Cleveland Clinic.

Speed matters: earlier referral to specialized centers is linked with better outcomes. Current recommendations are summarized in the peer-reviewed ESC/ERS Guidelines for pulmonary hypertension.

Can PAH be reversed?

There’s no one-size-fits-all cure, but PAH is increasingly treatable—and sometimes functionally reversible—especially when caught early. Many patients achieve low-risk status with modern, risk-based combination therapy, translating to improved exercise capacity, normalized biomarkers, and better right-heart function.

True reversal depends on the cause. Some congenital heart defects, when repaired promptly, can normalize lung pressures. Chronic thromboembolic pulmonary hypertension (CTEPH), which can mimic PAH, may be curable with surgical pulmonary endarterectomy (learn more) or treatable with balloon pulmonary angioplasty when surgery isn’t feasible (overview).

Treatment options: pathways and proven therapies

PAH therapy targets three main pathways that drive blood vessel narrowing and remodeling: endothelin, nitric oxide, and prostacyclin. Most patients benefit from guideline-based, risk-stratified combination therapy tailored to symptoms, right-heart function, and test results. The PHA’s treatment overview is a helpful primer.

Soluble guanylate cyclase (sGC) stimulator: riociguat

What it does: Riociguat (brand name Adempas) enhances the nitric oxide pathway to relax pulmonary arteries and reduce pressure. It’s approved for PAH and for inoperable or persistent/recurrent CTEPH.

Considerations: It can improve exercise capacity and hemodynamics but may cause low blood pressure, headache, dizziness, and reflux. It carries a boxed warning for embryo–fetal toxicity and requires strict pregnancy prevention and enrollment in a REMS program; it must not be combined with PDE5 inhibitors (sildenafil, tadalafil) or nitrates. See details in the FDA label for Adempas (riociguat).

Phosphodiesterase-5 (PDE5) inhibitors

Examples: Sildenafil (Revatio) and tadalafil (Adcirca) also augment the nitric oxide pathway and are widely used, often as part of initial dual therapy. Common side effects include headache, flushing, and nasal congestion; they should not be used with nitrates. Learn more about sildenafil and tadalafil.

Endothelin receptor antagonists (ERAs)

Examples: Ambrisentan, bosentan, and macitentan block endothelin, a potent vasoconstrictor. They improve symptoms and delay clinical worsening; macitentan and ambrisentan are commonly paired with PDE5 inhibitors in initial combination therapy. Side effects can include fluid retention and anemia; bosentan requires liver monitoring. Read more about macitentan.

Prostacyclin pathway therapies

Examples: Epoprostenol (IV), treprostinil (IV/subcutaneous/inhaled/oral), and iloprost (inhaled) are potent vasodilators and anti-remodeling therapies, particularly effective in advanced disease. The oral IP receptor agonist selexipag (Uptravi) extends this pathway to pill form. Continuous infusions can be life-saving but require catheter care and titration by experienced teams. Learn more about epoprostenol and selexipag.

Calcium channel blockers (for a small, tested subset)

A minority of patients demonstrate acute vasoreactivity during catheterization and may benefit from high-dose amlodipine, diltiazem, or nifedipine. This approach is only for the vasoreactive subset and should not be started without proper testing and specialist supervision.

Supportive care and advanced options

  • Diuretics to control swelling; weigh yourself daily and report sudden gains (e.g., >2 pounds overnight or >5 pounds in a week).
  • Oxygen if levels drop with activity or sleep; use as prescribed to protect the right heart.
  • Anticoagulation for CTEPH or select PAH patients as advised by specialists.
  • Cardiopulmonary rehabilitation improves endurance and confidence; find programs via the American Thoracic Society.
  • Transplantation (lung or heart–lung) for refractory, advanced cases after multidisciplinary evaluation.
  • Clinical trials: consider enrollment to access cutting-edge therapies (ClinicalTrials.gov).

Why early recognition changes outcomes

Starting therapy while the right ventricle is still compensating leads to better long-term results, fewer hospitalizations, and a higher chance of achieving low-risk status. Modern strategies often begin with dual oral therapy (ERA + PDE5 inhibitor) and escalate quickly to include riociguat or prostacyclin agents if targets aren’t met, following guideline-based risk assessment.

Track progress with measurable goals: walking distance (for example, the six-minute walk test), symptom class, NT-proBNP levels, and echocardiographic/right-heart catheter metrics. If goals aren’t met within a few months, ask your team about intensification or referral to a PH center with expertise in advanced therapies.

Living well with PAH: practical steps

  • Move safely: Light-to-moderate, supervised exercise is beneficial; avoid heavy lifting or breath-holding maneuvers.
  • Limit salt and monitor weight: Sudden gains can signal fluid retention—call your team.
  • Vaccinate: Stay current on influenza and pneumococcal vaccines to reduce lung infections.
  • Avoid high altitude and stop smoking: Low oxygen and tobacco strain the pulmonary circulation.
  • Plan pregnancy carefully: PAH and pregnancy carry high risk; discuss reliable contraception and preconception counseling.
  • Know your meds: Keep an updated list; avoid drug interactions (nitrates with PDE5 inhibitors; PDE5 inhibitors with riociguat).
  • Build a team: Partner with an experienced PH center and connect with reputable communities like the Pulmonary Hypertension Association.

When to seek urgent care

  • Chest pain, fainting, or severe breathlessness at rest
  • New confusion, blue lips, or coughing up blood
  • Rapid swelling—especially with decreased urine output

Key takeaways

  • Listen to early clues: progressive breathlessness, fatigue, and near-syncope are not “just being out of shape.”
  • Confirm the diagnosis quickly with echocardiography, a V/Q scan, and right heart catheterization.
  • PAH may not be curable, but early, aggressive, guideline-based therapy—including options like riociguat—can restore function and extend life.
  • Partner with a PH center, set measurable goals, and escalate therapy promptly if targets aren’t met.
  • If you’re experiencing persistent symptoms or have risk factors, schedule an appointment and bring a symptom diary. Early recognition is your greatest advantage.